Article Per Year (5 Year)
p-Index From 2020 - 2025
2.096
P-Index
This Author published in this journals
All Journal Jurnal Veteriner Jurnal Ilmiah Aplikasi Isotop Radiasi Microbiology Indonesia Media Penelitian dan Pengembangan Kesehatan Health Science Journal of Indonesia Medical Journal of Indonesia Universa Medicina Paediatrica Indonesiana Molecular and Cellular Biomedical Sciences (MCBS) The Indonesian Journal of Infectious Diseases JHECDs: Journal of Health Epidemiology and Communicable Diseases Journal of the Indonesian Medical Association : Majalah Kedokteran Indonesia Hubungan Tingkat Pengetahuan Petugas Pengelola Obat dengan Tingkat Ketersediaan Obat Di Puskesmas Kota Malang Daengku: Journal of Humanities and Social Sciences Innovation Indonesian Journal of Health Science Makara Journal of Science Makara Journal of Technology Jurnal Kefarmasian Indonesia
Budiman Bela
Departemen Mikrobiologi Fakultas Kedokteran Universitas Indonesia/KSM Mikrobiologi Klinik RSUPN Dr Cipto Mangunkusumo, Jakarta, Indonesia
Humanities Biochemistry, Genetics & Molecular Biology Chemical Engineering, Chemistry & Bioengineering Chemistry Civil Engineering, Building, Construction & Architecture Decision Sciences, Operations Research & Management Dentistry Education Electrical & Electronics Engineering Engineering Health Professions Immunology & microbiology Languange, Linguistic, Communication & Media Law, Crime, Criminology & Criminal Justice Materials Science & Nanotechnology Mechanical Engineering Medicine & Pharmacology Neuroscience Nursing Public Health Veterinary Other

Published : 29 Documents Claim Missing Document
Claim Missing Document
Check
Articles

Found 29 Documents
Search

 1   2   3 
Virological failure of first-line antiretroviral therapy in children living with HIV in Indonesia and associated factors Nia Kurniati; Zakiudin Munasir; Pramita Gayatri; Evy Yunihastuti; Budiman Bela; Anggraini Alam
Paediatrica Indonesiana Vol 62 No 5 (2022): September 2022
Publisher : Indonesian Pediatric Society

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.14238/pi62.5.2022.295-303

Abstract

Background The World Health Organization (WHO) recommends viral load (VL) monitoring for HIV patients on antiretroviral therapy (ART). However, availability of VL monitoring in low-income countries remains limited. Objective To investigate factors associated with virological failure in HIV-infected children treated without routine VL monitoring. Methods This cohort study was done in children living with HIV (CLHIV) registered at Cipto Mangunkusumo General Hospital from 2004 to 2021. Viral load monitoring was not routinely done. Subjects with at least one VL result after 6 months on ART were included in the study. Virological failure was defined as a VL of >1,000 copies. Subjects’ data were obtained from medical records, laboratory reports, and dispensing pharmacies. Statistical analysis was done following survival analysis with hazard ratio. Results There were 384 children who had at least 1 VL result after ART was initiated. Median age at diagnosis was 30 months. Length of follow-up ranged from 6 to 216 months, with a mean frequency of VL monitoring of 0.7 times/person/year. Most subjects were already in clinical stages 3 and 4 (77.8%); 75% met severe immunodeficiency criteria. Virological failure was found in 45.8% of subjects after a median of 33 months on first-line ART, yielding an incidence of 3.3 per 1,000 person months. Independent associated factors were age at diagnosis of <60 months (HR 1.714; 95%CI 1.13 to 2.6), severe immunodeficiency (HR 1.71; 95%CI 1.15 to 2.54), referral cases (HR 1.70; 95%CI 1.23 to 2.36), and WHO clinical staging 3 (HR 1.987; 95%CI 0.995 to 3.969) and 4 (HR 2.084; 95%CI 1.034 to 4.201). Subjects with virological failure had lower weight-for-age z-scores [median 1.92; interquartile range (IQR) -3.003 to -0.81] and height-for-age z-scores [median -2.05; IQR -2.902 to -1.04] at the time of failure. Conclusions In HIV-infected children treated without routine VL monitoring, age at diagnosis <60 months, severe immunodeficiency, WHO clinical stage 3 and 4, and referral from other centers were associated with virological failure.
The Use of Cell-penetrating Peptide for Delivery of Recombinant Transcription Factor DNA into Primary Human Fibroblast Melinda Remelia; Budiman Bela; Silvia Tri Widyaningtyas; Radiana Dhewayani Antarianto; Nuzli Fahdia Mazfufah; Jeanne Adiwinata Pawitan
Molecular and Cellular Biomedical Sciences Vol 7, No 1 (2023)
Publisher : Cell and BioPharmaceutical Institute

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21705/mcbs.v7i1.279

Abstract

Background: Reprogrammed cell therapy has not been applied for clinical purposes due to the malignancy issue. The aim of this study was to design the recombinant vector of the transcription factors and analyze the effectiveness of cell-penetrating peptide delivering system for human primary fibroblast transfection to avoid the malignancy issue.Materials and methods: The constructions of CCAT/enhancer binding protein alpha (CEBPA), hepatocyte nuclear factor 4 alpha (HNF4A), nuclear receptor subfamily 1 group I member 2 (NR1I2) were confirmed with DNA digestion and sequencing. Breast reduction (BRED) and palate (PAL) tissue were used as human primary fibroblast sources. The transcription factors were delivered into BRED and PAL with recombination of avian leukosis sarcoma virus (ALSV), human immunodeficiency virus (HIV) matrix, and regulator of expression of virion proteins (Rev) (ALMR), tagged with enhanced green fluorescence protein (eGFP). Post-transfection cells were then cultivated with optimized medium. Gene expression was measured with quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR).Results: Gene expression levels of CEBPA, HNF4A, NR1I2, glutamate-ammonia ligase (GLUL), albumin (ALB), and cytochrome P450 (CYP) were increased. Transfection with ALMR, which were more efficient in BRED than PAL fibroblasts may have the advantage in autologous cell therapy for elderly patients.Conclusion: Transfection of transcription factors to human primary fibroblast may be performed by using constructions of plasmid as designed in this study.Keywords: recombinant plasmid, hepatocyte-like cells, primary fibroblasts, recombinant peptide, cell reprogramming, autologous cells therapy
Cloning and Expression of HA1 Gene of H1N1 Influenza Virus 2009 Pandemic (H1n1pdm09) Indonesia Strain in the Pichia Pastoris Expression System for the Development of Influenza Vaccine ASRI SULFIANTI; ANDI YASMON; BUDIMAN BELA; FERA IBIRAHIM
Microbiology Indonesia Vol. 9 No. 2 (2015): June 2015
Publisher : Indonesian Society for microbiology

Show Abstract | Download Original | Original Source | Check in Google Scholar | Full PDF (1209.728 KB) | DOI: 10.5454/mi.9.2.7

Abstract

Among influenza viral proteins, hemagglutinin 1 (HA1) is the target for neutralizing antibodies which inhibit virus binding to receptor of target cells. This protein is widely developed as subunit recombinant vaccine. In this research, we expressed HA1 protein recombinant from DKI271/2011 Indonesian strain in Pichia pastoris. The identity of this protein was confirmed by western blotting using anti-His T ag and mouse specific antibody HA H1N1pdm09. The use of yeast P . pastoris as an alternative strategy to solve the problems which commonly found in influenza vaccine productions. Expression protein in E. coli has been known to have many problems, while mammalian and insect cells requires special skills and relatively high cost. The analysis of HA1 gene sequences showed no mutation in epitope region which recognized by T dan B cells. Further, this recombinant protein can be used as vaccine candidate in influenza vaccine development.Keywords: Hemagglutinin; Pichia pastoris; vaccine; Influenza Virus; H1N1pdm09.
Threat Analysis of Nipah Virus as a New Pandemic from the Perspective of Medical Intelligence Firdaus Sirait; Armi Susandi; Budiman Bela
Daengku: Journal of Humanities and Social Sciences Innovation Vol. 4 No. 1 (2024)
Publisher : PT Mattawang Mediatama Solution

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.35877/454RI.daengku2345

Abstract

According to World Health Organization (WHO), Nipah virus is a type of infectious disease from 10 types of infectious diseases that can pose a risk to the public health. Besides, it has the potential to become a new pandemic. The State Intelligence Agency has the authority, mandate, and responsibility to actively engage in early detection of a disease that could potentially become an epidemic and cause a threat to national security and interests. The formulation of this research problem is " Threat Analysis of Nipah Virus as a New Pandemic from the Perspective of a Medical Intelligence." The authors used a qualitative descriptive method approach through interviews and literature studies related to Nipah virus research. The results of the research indicated that the Nipah virus has the potential to become a new pandemic that can threaten the Indonesian people health and even the world. Thus, early detection of the Nipah virus spreading in Indonesia is necessary, by collaborating across ministries in implementing preventive measures using a one health concept approach.
TROUBLESHOOTING IN EXPRESSION AND PURIFICATION OF RECOMBINANT SEVERE ACUTE RESPIRATORY SYNDROME-ASSOCIATED CORONAVIRUS NUCLEOCAPSID PROTEIN IN Escherichia coli BL21 Yasmon, Andi; Ibrahim, Fera; Bela, Budiman
Makara Journal of Science Vol. 14, No. 2
Publisher : UI Scholars Hub

Show Abstract | Download Original | Original Source | Check in Google Scholar

Abstract

SARS-CoV-2 multi-epitope subunit vaccine proof-of-concept derived from the in silico study with protein expression in E. coli BL21 Muhayya, Syarifah Raisha; Agus Ariyanto, Ibnu; Widianingtyas, Silvia; Subiantistha, Tanaya; Bela, Budiman
Pharmaceutical Journal of Indonesia Vol. 9 No. 2 (2024)
Publisher : Brawijaya University

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.21776/ub.pji.2024.009.02.1

Abstract

The protein subunit vaccine is the most considerably developed SARS-Cov-2 vaccine, according to the WHO vaccine tracker in 2023. The acceleration of vaccine development in 2 years of eradicating the COVID-19 pandemic is attainable due to the role of bioinformatics. The objective of this paper is to evaluate strategies for developing multi-epitope SARS-Cov-2 recombinant vaccines with high protein expression in silico. The study was conducted by analyzing SARS-Cov-2 epitopes using immunoinformatics tools provided by IEDB, codon optimization, rare codon analysis, plasmid design, and ribosomal binding site (RBS) analysis were analyzed using RNA structure 6.4, gene cloning by E. coli DH5α and protein expression by E. coli BL21. Each epitope peptide candidate was linked to a flexible linker sequence (GGGGS). GelAnalyzer 19.1 was utilized to determine the protein band of SDS-PAGE. The immunoinformatics study obtained multi-epitope of the recombinant SARS-COV-2 vaccine with a total of 7 epitopes for HLA-I allele candidates and 4 for HLA-II. It is demonstrated that the candidate vaccine protein was successfully cloned in E. coli DH5α and expressed in E. coli BL21.
Respons imun seluler terhadap antigen E2, E6, dan E7 HPV16: Pemanfaatannya pencegahan dan terapi kanker serviks Utami, Mardhah Sastri; Bela, Budiman
Indonesian Journal of Health Science Vol 4 No 5 (2024)
Publisher : PT WIM Solusi Prima

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.54957/ijhs.v4i5.1088

Abstract

HPV merupakan kelompok virus penyebab kanker serviks. HPV16 menyebabkan 46-63% karsinoma sel skuamosa serviks. HPV16 terdiri dari 3 region siklus sel, yaitu early region (E), long control region (LCR), dan late region (L). Early region yang berasal dari protein E1, E2, E4, E5, E6, dan E7 berperan dalam ekspresi gen virus, replikasi virus, dan siklus hidup virus. Virus akan mengekspresikan protein E1 dan E2 kemudian terjadi delesi, dan sel yang terinfeksi akan berdiferensiasi dan mengekspresikan E6 dan E7. Ekspresi E6 dan E7 akan menurunkan ekspresi TLR9, IFN-1, dan supresi sitokin proinflamasi. Respons imun yang menurun menyebabkan sel yang terinfeksi berdiferensiasi menjadi sel kanker. Vaksinasi profilaksis digunakan sebagai pencegahan dan pengendalian infeksi virus HPV16, tetapi tidak dapat melindungi individu yang sudah terinfeksi dari perkembangan infeksi virus dan sel abnormal. Oleh karena itu, vaksinasi terapeutik diperlukan untuk imunoterapi kanker. Antigen HPV16 yang terdiri dari E2, E6, dan E7 diharapkan menjadi target yang baik. Antigen E2, E6, dan E7 bertujuan untuk mengaktifkan respons imun spesifik yang diperantarai sel untuk memfagositosis sel yang terinfeksi. Antigen diproses oleh sel dendritik dan kemudian disajikan kepada molekul MHC. MHC II akan merangsang respons sel T CD4+ terhadap protein yang akan membantu sel T CD8+ sitotoksik. Antigen disajikan oleh MHC I untuk dipresentasikan ke sel T CD8+ sitotoksik untuk mengeliminasi sel yang terinfeksi. Antigen E2, E6, dan E7 untuk imunoterapi guna mencegah perkembangan sel abnormal sehingga tidak berkembang menjadi kanker.
Uji In Vitro Beberapa Kombinasi Antibiotik Antipseudomonas terhadap Pseudomonas aeruginosa yang Resisten terhadap Karbapenem Prasetyo, Dimas Seto; Herna, Herna; Mursinah, Mursinah; Ibrahim, Fera; Bela, Budiman
Jurnal Kefarmasian Indonesia VOLUME 12, NOMOR 1, FEBRUARI 2022
Publisher : Pusat Penelitian dan Pengembangan Biomedis dan Teknologi Dasar Kesehatan

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.22435/jki.v0i0.5008

Abstract

Lower respiratory tract, sepsis, or urinary tract infection caused by the multidrug resistance Pseudomonas aeruginosa is common in the hospital, especially in the ICU wards. The treatment against this bacteria requires combination of antibiotics with different mechanism of actions. In this study, several combinations of antibiotics were evaluated in vitro against carbapenem-resistant P. aeruginosa isolated from the ICU of Cipto Mangunkusumo Hospital. The combination of antibiotics tested were ceftazidime-amikacin, ceftazidime-ciprofloxacin, and ciprofloxacin-amikacin. Checkerboard assay to the combination of antibiotics was conducted to assess the in vitro synergistic activity. A total of 22 P. aeruginosa isolates were collected, 16 of them were resistant to ceftazidime, ciprofloxacin, amikacin, as well as carbapenem. The result revealed that the combination of ceftazidime and amikacin showed promising synergistic activity. Conversely, no synergitic activities were shown by the combination of ceftazidime-ciprofloxacin and ciprofloxacin-amikacin. The combination of ceftazidime-amikacin may has potential effect againsts carbapenem-resistant P. aeruginosa in vitro.
Mengatasi Tantangan Skrining HPV pada Perempuan: Sebuah Kajian Umum Bela, Budiman; Hartono, Soni; Pratiwi, Ekawati Betty; Cahyani, Hesti Pramesti; Widyaningtyas, Silvia Tri
Majalah Kedokteran Indonesia Vol 75 No 2 (2025): Journal of The Indonesian Medical Association - Majalah Kedokteran Indonesia, Vo
Publisher : PENGURUS BESAR IKATAN DOKTER INDONESIA (PB IDI)

Show Abstract | Download Original | Original Source | Check in Google Scholar | DOI: 10.47830/jinma-vol.75.2-2025-1898

Abstract

Introduction: A major challenge in the success of HPV screening programs is achieving 70% coverage of women aged 30-69. This study conducted a survey to examine the factors influencing the willingness of woman in that age group to actively engage HPV screening program.Method: Socio-demographic data, knowledge levels, cervical cancer screening uptake, and willingness to participate in the government’s routine screening program were collected digitally using cross-sectional study. Factors associated with knowledge, participation, and willingness to engage program measured using logistic regression analysis.Result: Among the 87 eligible respondents, 96.6% had heard about cervical cancer mostly via internet, and 51% categorized as having low level knowledge. The percentage of participants willingness to participate in program was 67.82% below the percentage government target coverage. Factors correlated with willingness included: age group 36-40 (aOR = 1.865, 95% CI = 0.567-6.129) and 41-45 (aOR = 2.93, 95% CI = 0.762-11.272), monthly household expense (aOR = 1.682, 95% CI = 0.684-4.138), having relatives suffer cervical cancer (aOR = 2.764, 95% CI = 0.790-9.672), history of HPV vaccination (aOR = 1.187, 95% CI = 0.593-7.539).Conclusion: Respondent willingness to participate in HPV screening program remains to be improved. Various ways to increase participation in screening programs need to be developed to reach various populations of women.
Co-Authors Ade P.R. Simaremare Andi Yasmon Andrijono Andrijono Anggraini Alam Anis Anis Ardiana Kusumaningrum Armi Susandi Aroem Naroeni Aroem Naroeni Ascobat, Purwantyastuti ASRI SULFIANTI Beti Ernawati Dewi Cahyani, Hesti Pramesti Christina, Diana Cintera Rahmagiarti Diah Iskandriati Dian Amirulloh Dimas Seto Prasetyo Dondin Sajuthi Elisna Syahruddin Evy Yunihastuti FERA IBIRAHIM Fera Ibrahim Firdaus Sirait Ganjar Noviar Gede Eko Darmono Geraldine, Vanessa Hanifi, Muhammad Hartiyowidi Yuliawuri Hartono, Soni Herna Herna Herna, Herna Hertanto, Robby Ibnu Agus Ariyanto Iin Maemunah Ingrid S. Surono Jeanne Adiwinata Pawitan Jeanne Elvia Christian Kamila, Etri Dian Ketut Tuti Parwati Lili Indrawati Maria Lina R. Maria Lina Rosilawati Melinda Remelia Muhayya, Syarifah Raisha Murdani Abdullah Mursinah Mursinah Mursinah Mursinah Ni Ken Ritchie Ni Nengah Dwi Fatmawati Nia Kurniati Nuzli Fahdia Mazfufah Pamungkas, Joko Pauline Phoebe Halim Pramita Gayatri Pratiwi, Ekawati Betty Radiana Dhewayani Antarianto SAHLAN, MUHAMAD Sari, Siska Yuliana Satyapertiwi, Dwiantari Silvia Tri Widyaningtyas Silvia Tri Widyaningtyas Silvia Tri Widyaningtyas Silvia Tri Widyaningtyas Silvia Tri Widyaningtyas Silvia Triwidyaningtyas Sofy Meilany Subangkit Subangkit Subiantistha, Tanaya Sugiarta, Gede Yuda SUWIJIYO PRAMONO Utami, Mardhah Sastri VIVI SETIAWATY Widianingtyas, Silvia Widyaningtyas, Silvia Tri Wiseso, Anggoro Yohda, Masafumi YULIANTY MUHAYAR Yuliar Budi Hartanto Yusmaniar Yusmaniar Yuyun SM Soedarmono Yuyun Soedarmono Zakiudin Munasir